# Maria Jesus Perugorria

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 43 papers | 4,352 citations | 257450 24 h-index | 254184 43 g-index |
| 43 all docs | 43 docs citations | 43 times ranked | 5550 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 557-588. | 17.8 | 1,155 |
| 2 | Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nature Reviews Gastroenterology and Hepatology, 2016, 13, 261-280. | 17.8 | 964 |
| 3 | Wntâ€“Î²-catenin signalling in liver development, health and disease. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 121-136. | 17.8 | 341 |
| 4 | Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. Hepatology, 2017, 66, 1125-1143. | 7.3 | 218 |
| 5 | Stimulating healthy tissue regeneration by targeting the 5-HT2B receptor in chronic liver disease. Nature Medicine, 2011, 17, 1668-1673. | 30.7 | 177 |
| 6 | The tumour microenvironment and immune milieu of cholangiocarcinoma. Liver International, 2019, 39, 63-78. | 3.9 | 109 |
| 7 | Histone methyltransferase ASH1 orchestrates fibrogenic gene transcription during myofibroblast transdifferentiation. Hepatology, 2012, 56, 1129-1139. | 7.3 | 108 |
| 8 | Non-parenchymal TREM-2 protects the liver from immune-mediated hepatocellular damage. Gut, 2019, 68, 533-546. | 12.1 | 96 |
| 9 | SOX17 regulates cholangiocyte differentiation and acts as a tumor suppressor in cholangiocarcinoma. Journal of Hepatology, 2017, 67, 72-83. | 3.7 | 81 |
| 10 | Polycystic liver diseases: advanced insights into the molecular mechanisms. Nature Reviews Gastroenterology and Hepatology, 2014, 11, 750-761. | 17.8 | 80 |
| 11 | Pathobiology of inherited biliary diseases: a roadmap to understand acquired liver diseases. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 497-511. | 17.8 | 73 |
| 12 | MicroRNAâ€506 promotes primary biliary cholangitisâ€“like features in cholangiocytes and immune activation. Hepatology, 2018, 67, 1420-1440. | 7.3 | 72 |
| 13 | The search for novel diagnostic and prognostic biomarkers in cholangiocarcinoma. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 1468-1477. | 3.8 | 72 |
| 14 | Patients with Cholangiocarcinoma Present Specific RNA Profiles in Serum and Urine Extracellular Vesicles Mirroring the Tumor Expression: Novel Liquid Biopsy Biomarkers for Disease Diagnosis. Cells, 2020, 9, 721. | 4.1 | 63 |
| 15 | Pathogenesis of Cholangiocarcinoma. Annual Review of Pathology: Mechanisms of Disease, 2021, 16, 433-463. | 22.4 | 63 |
| 16 | PNPLA3 p.I148M variant is associated with greater reduction of liver fat content after bariatric surgery. Surgery for Obesity and Related Diseases, 2016, 12, 1838-1846. | 1.2 | 60 |
| 17 | TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms. Gut, 2021, 70, 1345-1361. | 12.1 | 59 |
| 18 | Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease. Journal of Hepatology, 2015, 63, 952-961. | 3.7 | 56 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Inhibition of metalloprotease hyperactivity in cystic cholangiocytes halts the development of polycystic liver diseases. Gut, 2014, 63, 1658-1667. | 12.1 | 55 |
| 20 | MicroRNA (miR)â€433 and miRâ€22 dysregulations induce histoneâ€deacetylaseâ€6 overexpression and ciliary loss in cholangiocarcinoma. Hepatology, 2018, 68, 561-573. | 7.3 | 54 |
| 21 | Tumor progression locus 2/Cot is required for activation of extracellular regulated kinase in liver injury and toll-like receptor-induced TIMP-1 gene transcription in hepatic stellate cells in mice. Hepatology, 2013, 57, 1238-1249. | 7.3 | 41 |
| 22 | Primary biliary cholangitis: A tale of epigenetically-induced secretory failure?. Journal of Hepatology, 2018, 69, 1371-1383. | 3.7 | 35 |
| 23 | Elevated interleukinâ€8 in bile of patients with primary sclerosing cholangitis. Liver International, 2016, 36, 1370-1377. | 3.9 | 34 |
| 24 | Extracellular Vesicles in Hepatobiliary Malignancies. Frontiers in Immunology, 2018, 9, 2270. | 4.8 | 29 |
| 25 | FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted. Journal of Hepatology, 2021, 75, 363-376. | 3.7 | 29 |
| 26 | E2F1 and E2F2-Mediated Repression of CPT2 Establishes a Lipid-Rich Tumor-Promoting Environment. Cancer Research, 2021, 81, 2874-2887. | 0.9 | 27 |
| 27 | Proteostasis disturbances and endoplasmic reticulum stress contribute to polycystic liver disease: New therapeutic targets. Liver International, 2020, 40, 1670-1685. | 3.9 | 22 |
| 28 | TREM-2 plays a protective role in cholestasis by acting as a negative regulator of inflammation. Journal of Hepatology, 2022, 77, 991-1004. | 3.7 | 22 |
| 29 | MicroRNAs in cholangiopathies: Potential diagnostic and therapeutic tools. Clinics and Research in Hepatology and Gastroenterology, 2016, 40, 15-27. | 1.5 | 20 |
| 30 | TPL2 Kinase Is a Crucial Signaling Factor and Mediator of NKT Effector Cytokine Expression in Immune-Mediated Liver Injury. Journal of Immunology, 2016, 196, 4298-4310. | 0.8 | 16 |
| 31 | Effect of pravastatin on the survival of patients with advanced gastric cancer. Oncotarget, 2016, 7, 4379-4384. | 1.8 | 15 |
| 32 | Novel causative genes for polycystic liver disease. Nature Reviews Gastroenterology and Hepatology, 2017, 14, 391-392. | 17.8 | 15 |
| 33 | Cholangiocarcinoma progression depends on the uptake and metabolization of extracellular lipids. Hepatology, 2022, 76, 1617-1633. | 7.3 | 15 |
| 34 | Genetics, pathobiology and therapeutic opportunities of polycystic liver disease. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 585-604. | 17.8 | 15 |
| 35 | Targeting UBC9-mediated protein hyper-SUMOylation in cystic cholangiocytes halts polycystic liver disease in experimental models. Journal of Hepatology, 2021, 74, 394-406. | 3.7 | 14 |
| 36 | Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models. Journal of Hepatology, 2022, 77, 177-190. | 3.7 | 11 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Bile Acids in Polycystic Liver Diseases: Triggers of Disease Progression and Potential Solution for Treatment. Digestive Diseases, 2017, 35, 275-281. | 1.9 | 8 |
| 38 | Synthetic Conjugates of Ursodeoxycholic Acid Inhibit Cystogenesis in Experimental Models of Polycystic Liver Disease. Hepatology, 2021, 73, 186-203. | 7.3 | 7 |
| 39 | Inhibition of NAEâ€dependent protein hyperâ€NEDDylation in cystic cholangiocytes halts cystogenesis in experimental models of polycystic liver disease. United European Gastroenterology Journal, 2021, 9, 848-859. | 3.8 | 7 |
| 40 | Cholangiocyteâ€toâ€Hepatocyte Differentiation: A Contextâ€Dependent Process and an Opportunity for Regenerative Medicine. Hepatology, 2019, 69, 480-483. | 7.3 | 6 |
| 41 | Toward personalized medicine for intrahepatic cholangiocarcinoma: Pharmacogenomic stratification of patients. Hepatology, 2018, 68, 811-814. | 7.3 | 4 |
| 42 | O-GlcNAcylation: Undesired tripmate but an opportunity for treatment in NAFLD-HCC. Journal of Hepatology, 2017, 67, 218-220. | 3.7 | 3 |
| 43 | More insight into the diversity of cholangiocyte ciliopathies. Journal of Hepatology, 2016, 65, 1083-1085. | 3.7 | 1 |